Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:IKTNASDAQ:OKYONASDAQ:PMNNYSEARCA:SBMNASDAQ:VRDN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIKTInhibikase Therapeutics$2.30+0.4%$2.38$0.79▼$4.68$14.14M1.1952,872 shs14,636 shsOKYOOKYO Pharma$1.49+3.5%$1.48$0.92▼$3.25$41.52MN/A171,655 shs43,249 shsPMNProMIS Neurosciences$1.75-9.8%$2.01$0.95▼$8.95$33.06M0.6845,265 shs8,173 shsSBMProShares Short Basic Materials$46.38$46.38$42.85▼$55.15$1.86MN/A3,024 shsN/AVRDNViridian Therapeutics$17.51+0.8%$18.74$10.93▼$30.30$1.09B1.081.17 million shs707,704 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIKTInhibikase Therapeutics+0.44%+12.20%+3.60%+88.52%-47.37%OKYOOKYO Pharma+3.47%-15.82%+5.67%-21.16%+12.88%PMNProMIS Neurosciences-9.79%-10.71%-17.84%+56.25%-62.45%SBMProShares Short Basic Materials0.00%0.00%0.00%0.00%-0.01%VRDNViridian Therapeutics+0.81%-3.26%-9.13%-21.80%-30.07%Central Banks Preparing for US Dollar Collapse? (Ad)China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIKTInhibikase Therapeutics2.3887 of 5 stars3.50.00.00.02.41.71.3OKYOOKYO Pharma2.9285 of 5 stars3.55.00.00.02.01.70.6PMNProMIS Neurosciences2.3173 of 5 stars3.53.00.00.02.41.70.6SBMProShares Short Basic MaterialsN/AN/AN/AN/AN/AN/AN/AN/AVRDNViridian Therapeutics1.6539 of 5 stars3.51.00.00.02.51.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIKTInhibikase Therapeutics3.00Buy$27.001,073.91% UpsideOKYOOKYO Pharma3.00Buy$7.00369.80% UpsidePMNProMIS Neurosciences3.00Buy$8.00357.14% UpsideSBMProShares Short Basic Materials0.00N/AN/AN/AVRDNViridian Therapeutics3.00Buy$36.60109.02% UpsideCurrent Analyst RatingsLatest PMN, IKT, OKYO, VRDN, and SBM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/22/2024OKYOOKYO PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.00 ➝ $7.003/21/2024VRDNViridian TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$29.00 ➝ $25.003/20/2024VRDNViridian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.003/5/2024IKTInhibikase TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.002/29/2024VRDNViridian TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.002/28/2024VRDNViridian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.002/28/2024VRDNViridian TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$39.00 ➝ $40.001/8/2024OKYOOKYO PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIKTInhibikase Therapeutics$120K118.26N/AN/A$4.50 per share0.51OKYOOKYO PharmaN/AN/AN/AN/A($0.08) per shareN/APMNProMIS Neurosciences$10K3,305.75N/AN/A($0.16) per share-10.94SBMProShares Short Basic MaterialsN/AN/AN/AN/AN/AN/AVRDNViridian Therapeutics$314K3,500.22N/AN/A$4.48 per share3.91Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIKTInhibikase Therapeutics-$18.05M-$3.95N/AN/AN/A-5,886.15%-94.66%-81.99%3/29/2024 (Estimated)OKYOOKYO Pharma-$13.27MN/A0.00N/AN/AN/AN/AN/AN/APMNProMIS Neurosciences-$18.06M-$1.94N/AN/AN/AN/AN/A-219.98%N/ASBMProShares Short Basic MaterialsN/AN/A0.00∞N/AN/AN/AN/AN/AVRDNViridian Therapeutics-$237.73M-$5.32N/AN/AN/A-75,711.48%-121.80%-61.06%5/14/2024 (Estimated)Latest PMN, IKT, OKYO, VRDN, and SBM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/27/2024Q4 2023VRDNViridian Therapeutics-$0.98-$1.35-$0.37-$1.35$0.15 million$0.07 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/APMNProMIS NeurosciencesN/AN/AN/AN/AN/ASBMProShares Short Basic MaterialsN/AN/AN/AN/AN/AVRDNViridian TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIKTInhibikase TherapeuticsN/A6.406.40OKYOOKYO PharmaN/AN/AN/APMNProMIS NeurosciencesN/A1.811.81SBMProShares Short Basic MaterialsN/AN/AN/AVRDNViridian Therapeutics0.0918.2618.26OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIKTInhibikase Therapeutics3.81%OKYOOKYO Pharma2.97%PMNProMIS Neurosciences50.13%SBMProShares Short Basic MaterialsN/AVRDNViridian TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipIKTInhibikase Therapeutics20.30%OKYOOKYO Pharma40.46%PMNProMIS Neurosciences10.30%SBMProShares Short Basic MaterialsN/AVRDNViridian Therapeutics1.43%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableIKTInhibikase Therapeutics66.17 million4.92 millionNot OptionableOKYOOKYO Pharma828.83 million17.17 millionNot OptionablePMNProMIS Neurosciences618.89 million16.94 millionNot OptionableSBMProShares Short Basic MaterialsN/A40,000N/ANot OptionableVRDNViridian Therapeutics9462.77 million61.87 millionOptionablePMN, IKT, OKYO, VRDN, and SBM HeadlinesSourceHeadlineAnalysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), OmniAb (OABI) and Vericel (VCEL)markets.businessinsider.com - March 25 at 10:01 PMViridian Therapeutics, Inc. to Post FY2028 Earnings of $3.76 Per Share, B. Riley Forecasts (NASDAQ:VRDN)americanbankingnews.com - March 25 at 3:04 AMViridian Therapeutics (NASDAQ:VRDN) Stock Price Down 4.7% on Analyst Downgradeamericanbankingnews.com - March 23 at 1:30 AMViridian Therapeutics (NASDAQ:VRDN) Stock Price Down 4.7% Following Analyst Downgrademarketbeat.com - March 22 at 12:27 PMViridian Therapeutics (NASDAQ:VRDN) PT Lowered to $25.00 at B. Rileyamericanbankingnews.com - March 22 at 6:34 AMB. Riley Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $25.00marketbeat.com - March 21 at 10:55 AMViridian Therapeutics (NASDAQ:VRDN) Stock Rating Reaffirmed by Needham & Company LLCamericanbankingnews.com - March 21 at 4:58 AMBuy Rating Endorsed for Viridian Therapeutics’ VRDN Treatments Based on Superior Efficacy and Dosing Advantages in TED Marketmarkets.businessinsider.com - March 20 at 8:21 PMUnveiling 4 Analyst Insights On Viridian Therapeuticsmarkets.businessinsider.com - March 20 at 3:20 PMViridian Therapeutics (NASDAQ:VRDN) Given Buy Rating at Needham & Company LLCmarketbeat.com - March 20 at 1:44 PMFinding the Next Big Winners: 3 Stocks You Can Snag for Under $20investorplace.com - March 19 at 6:51 PMVRDN Sep 2024 20.000 putfinance.yahoo.com - March 16 at 8:46 AMVRDN Apr 2024 20.000 putfinance.yahoo.com - March 16 at 8:46 AMSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firmstockhouse.com - March 15 at 11:23 PMViridian Therapeutics (NASDAQ:VRDN) Shares Down 8.4% marketbeat.com - March 12 at 1:24 PMVRDN Makes Bullish Cross Above Critical Moving Averagenasdaq.com - March 9 at 2:40 PMSchonfeld Strategic Advisors LLC Grows Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)marketbeat.com - March 9 at 5:42 AMViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com - March 6 at 4:01 PMViridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conferencefinance.yahoo.com - March 5 at 10:27 AMCharles Schwab Investment Management Inc. Increases Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)marketbeat.com - March 5 at 4:35 AMConnor Clark & Lunn Investment Management Ltd. Sells 67,587 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)marketbeat.com - March 2 at 6:17 AMBraidwell LP Acquires 528,882 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)marketbeat.com - March 1 at 10:18 AMViridian Therapeutics, Inc. Expected to Post FY2024 Earnings of ($5.72) Per Share (NASDAQ:VRDN)marketbeat.com - March 1 at 8:02 AMBuy Rating Affirmed for Viridian Therapeutics Amid Strong Clinical Progress and Market Potentialmarkets.businessinsider.com - March 1 at 8:01 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple Ways5 Under-the-Radar Artificial Intelligence (AI) Stocks March 4, 2024 9:30 AMView 5 Under-the-Radar Artificial Intelligence (AI) Stocks Your Comprehensive Guide to Investing in Bank StocksMarch 1, 2024 10:41 AMView Your Comprehensive Guide to Investing in Bank StocksCathie Wood Likes UiPath Stock Over NVDA, Should You?March 5, 2024 7:00 AMView Cathie Wood Likes UiPath Stock Over NVDA, Should You?Google and Meta Circling the Market on a TikTok Ban RallyMarch 21, 2024 12:58 PMView Google and Meta Circling the Market on a TikTok Ban RallyAll Headlines Company DescriptionsInhibikase TherapeuticsNYSE:IKTInhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.OKYO PharmaNASDAQ:OKYOOKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.ProMIS NeurosciencesNASDAQ:PMNProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.ProShares Short Basic MaterialsNYSEARCA:SBMProShares Short Basic Materials (the Fund) seeks daily investment results that correspond to the inverse (opposite) of the daily performance of Dow Jones U.S. Basic Materials Index (the Index). The Index measures the performance of the basic materials industry of the United States equity market. The Fund invests in derivatives as a substitute for directly shorting stocks in order to gain inverse exposure to the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. The Fund also invests in short-term cash instruments that have terms to maturity of less than 397 days and exhibit credit profiles. ProShare Advisors LLC is the investment advisor of the Fund.Viridian TherapeuticsNASDAQ:VRDNViridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.